CTIS.eu › Conditions › Breast cancer
Breast cancer
77 total trials
45 recruiting
MedDRA PT
2022-501312-34-00
6
2024-512152-38-00
9
2024-517993-94-00
4
"Breast Cancer"
2024-518326-32-00
7
"Patients with advanced solid malignancies that have progress"
2025-524613-89-00
9
"HER2 positive advanced breast cancer"
2025-521983-36-00
4
2026-06-12
"Colorectal cancer (CRC), gastric cancer (GC), pancreatic duc"
2025-522484-15-00
5
2026-04-27
"ER+/HER2- early breast cancer"
2025-523204-68-00
4
2026-03-25
"HER2-positive breast cancer"
2025-521884-12-00
5
2026-03-19
"First line triple-negative breast cancer (TNBC)"
2024-516282-37-00
4
2025-02-18
2022-501152-28-00
4
2022-12-21
"Breast Cancer"
2024-517746-34-00
1
2026-06-26
"Advanced breast cancer and advanced NSCLC"
2024-516551-41-00
4
2026-03-06
"Patients with HER2-expressing solid tumors"
2024-517979-20-00
9
2026-03-04
"Advanced Breast Cancer
Metastatic Breast Cancer"
2025-521128-31-00
9
2025-12-18
"Locally Advanced or Metastatic Estrogen Receptor-Positive, h"
2025-522233-62-00
7
2025-12-12
"Advanced cancer; breast cancer; metastatic gastric / gastroe"
2024-511392-15-00
5
2025-11-20
"HR+/HER2- advanced breast cancer"
2024-520290-12-00
6
2025-11-04
"Hormone receptor–positive (HRpos)/human epidermal growth fac"
2024-512421-92-00
7
2025-10-14
"Unresectable, Locally Advanced or Metastatic Cancer"
2025-521497-34-00
1
2025-10-06
"Neuroblastoma"
2024-516786-37-00
1
2025-09-22
"Patients with breast cancer, gastroesophageal adenocarcinoma"
2024-516870-31-00
1
2025-07-11
"Endometrial Carcinoma"
2023-509598-22-01
6
2025-05-13
"Oncology - Breast cancer"
2024-516173-76-01
5
2025-04-22
"HER2-positive or HER2-low (incl. ultra-low) early breast can"
Showing 1–24 of 77 trials